| Khoom npe | Navitoclax |
| Alias | AB-263 |
| CAS Nr. | 923564‑51‑6 |
| Qhov tshwm sim | Dawb mus rau lub teeb-daj crystalline hmoov |
| Molecular Formula | C₄₇H₅₅ClF₃N₅O₆S₃ |
| Molecular Luj | 974,61 g / mol |
| Purity | Ntau dua lossis sib npaug li 98% (HPLC) |
| Pob | Txias-pack / ice-pack tsheb thauj mus los, yuav tsum muaj teeb pom kev zoo |
| Cia | Khaws -20 degree, kaw, qhuav thiab tsaus, tsis txhob ya raws thiab rov ua kom khov-thaw mus |
| Txee-Lub neej | 24 Lub Hlis |
Khoom Description
Navitoclax (ABT-263) yog dab tsi?
Navitoclax, tseem hu ua ABT-263, yog qhov ncauj qhov ncauj bioavailable me me-molecule BH3-mimetic compound, CAS 923564-51-6. Nws ua raws li lub zog xaiv inhibitor tsom rau cov tshuaj tiv thaiv apoptotic Bcl-2 tsev neeg cov proteins suav nrog Bcl-2, Bcl-xL thiab Bcl-w, nrog sub-nanomolar binding affinity (Ki tsawg dua lossis sib npaug li 1 nM) thaum uas qhia tsis muaj zog rau Mcl-1 thiab A1. Raws li kev tshawb fawb-qib cov khoom siv tshuaj, cov hmoov purity siab no tau siv dav rau kev tshawb fawb ua ntej kev kho mob oncology, kev tshawb nrhiav apoptosis txoj hauv kev thiab kev tshawb fawb txog senolytic. Rau kev tshawb fawb siv nkaus xwb. Tsis yog rau tib neeg lossis kev kho mob.
Cov khoom zoo sib xws rau Navitoclax (ABT-263) Kev Tshawb Fawb Kev Siv Tsuas
| Khoom npe | Alias | CAS Nr. |
| AB-737 | ABT737 | 852808‑04‑9 |
| Venetoclax | AB-199 | 1257044‑40‑8 |
| A1331852 | ‑ | 1438287‑87‑8 |
| Obatoclax Mesylate | TX15-070 | 803712‑67‑6 |
| S63845 | ‑ | 1799633‑27‑4 |
| TWS-37 | ‑ | 877877‑35‑5 |
Daim ntawv thov ntawm ABT-263
1.Oncology & Apoptosis Mechanism Kev Tshawb Fawb: Kawm Bcl-2/Bcl-xL-dependent apoptosis; khiav cell-raws li kev soj ntsuam rau cov qog hematological thiab cov qog nqaij hlav ua ntej kev kho mob; soj ntsuam anti-tumor compound ua ke los.
2.Senolytic / Cellular Senescence Kev Tshawb Fawb: Cov cuab yeej siv cuab yeej cuab tam rau kev tshem tawm cov hlwb senescent; dav siv rau kev laus-txog txog biology, senescence-triggered qog-relapse tshawb fawb hauv tsiaj qauvPMC.
3.Target validation & Drug Discovery: Bcl-2-tsev neeg lub hom phiaj validation; BH3-profiling kev sim; Kev tshawb fawb tiv thaiv-txhim kho (Mcl-1-mediated drug resistance); hit-to-lead pre-clinical compound screening.
4.In-vitro & In-vivo Lab Assays: Npaj DMSO cov kev daws teeb meem rau cov kab lis kev cai ntawm tes; Kev tshawb fawb ntawm qhov ncauj hauv cov qauv nas xenograft rau kev kuaj tshuaj kho mob ua ntej.
Cov txiaj ntsig ntawm ABT-263
High-potency phiaj khi: Sub-nanomolar affinity rau Bcl-2 / Bcl-xL / Bcl-w; zoo-txhais hom phiaj xaiv profile rau kev kawm mechanism.
Orally bio-muaj cov khoom muaj tshuaj lom neeg: Haum rau ob qho tib si hauv vitro cell assay thiab qhov ncauj-dosing in-vivo xenograft tsiaj qauv.
Induces intrinsic apoptosis nyob rau hauv rhiab cell pej xeem: Ua kom muaj kev tshawb fawb ntawm mitochondrial-dependent cell-death txoj hauv kev tshawb fawb oncology American .
Cov yam ntxwv zoo ntawm senolytic kev ua ub no: Kub-tus qauv cuab yeej reagent rau senescence-txog txog biology, senescent-cell clearance thwmsim.
Txhawb kev tshawb fawb txog tshuaj ua ke: Tso cai rau kev soj ntsuam ntawm kev sib koom ua ke thaum ua ke nrog cov kws khomob lossis cov neeg ua haujlwm tsom rau kev kuaj mob ua ntej.
Clear selectivity sib txawv vs Mcl-1: Pab tau rau kev kawm tshuaj tiv thaiv mechanisms tsav los ntawm Mcl-1 overexpression.
Cov lus teb rau cov neeg siv khoom
Hu rau PAGE
Peb muab siab-purity Navitoclax (ABT-263, CAS 923564-51-6) rau kev tshawb fawb siv nkaus xwb. Cov qauv thiab ntau ntau muaj nrog COA thiab SDS cov ntaub ntawv. Thov hu rau peb ntawm tus nqi, specifications thiab hais.
1.Nrhiav txoj kev:
Email: alice@xaheshun.com
whatspp: +8618509260106
Online instant messaging
2. Hu rau cov ntaub ntawv:
Lub npe: Alice
Xov tooj: +8618509260106
Email: alice@xaheshun.com
FAQ
Q: CAS Navitoclax yog dab tsi?
A: Tus lej CAS Navitoclax (ABT-263) yog 923564-51-6.
Q: Dab tsi purity qib koj muab rau ABT-263??
A: Peb muab siab purity Ntau dua lossis sib npaug rau 98% HPLC qib Navitoclax. HPLC, NMR thiab COA cov ntaub ntawv xeem muaj los pab txhawb kev tshawb fawb hauv chav kuaj thiab kev txheeb xyuas batch.
Q: Dab tsi yog qhov chaw cia kom raug rau Navitoclax hmoov?
A: Khaws kaw ntawm -20℃nyob rau hauv qhuav thiab tsaus ntuj. Tsis txhob rov qab khov-thaw cycles. Cov hmoov khaws cia kom zoo tswj kev ruaj ntseg mus txog 3 xyoos.
Q: Qhov txawv ntawm Navitoclax (ABT-263) thiab ABT-737 yog dab tsi?
A: Ob leeg yog BH3-mimetic Bcl-2 tsev neeg inhibitors. Navitoclax muaj qhov zoo ntawm qhov ncauj bioavailability thiab hauv vivo stability, thaum ABT-737 feem ntau yog siv rau hauv vitro cell-theem mechanism tshawb fawb.
Q: Navitoclax (ABT-263) siv rau dab tsi?
A: Navitoclax (ABT-263) yog kev tshawb fawb-qib BH3-mimetic inhibitor tsom rau Bcl-2, Bcl-xL thiab Bcl-w. Nws yog dav siv rau hauv vitro cell assays, hauv vivo tsiaj qauv kev tshawb fawb, oncology mechanism kev tshawb fawb, apoptosis tsom xam thiab kev tshawb fawb txog senolytic.
Cim npe nrov: Tuam Tshoj siab purity navitoclax (abt-263) cas 923564-51-6, Tuam Tshoj siab purity navitoclax (abt-263) cas 923564-51-6 manufacturers, lwm tus neeg, Hoobkas
